Xiaofei Zhou

1.7k total citations
79 papers, 1.2k citations indexed

About

Xiaofei Zhou is a scholar working on Oncology, Cell Biology and Molecular Biology. According to data from OpenAlex, Xiaofei Zhou has authored 79 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Oncology, 31 papers in Cell Biology and 25 papers in Molecular Biology. Recurrent topics in Xiaofei Zhou's work include Microtubule and mitosis dynamics (30 papers), Cancer-related Molecular Pathways (17 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Xiaofei Zhou is often cited by papers focused on Microtubule and mitosis dynamics (30 papers), Cancer-related Molecular Pathways (17 papers) and Chronic Lymphocytic Leukemia Research (11 papers). Xiaofei Zhou collaborates with scholars based in United States, Japan and China. Xiaofei Zhou's co-authors include Richard G. Compton, Wei Cheng, Hadi Danaee, Karthik Venkatakrishnan, Howard Fingert, E. Jane Leonard, Hua Liu, Daniel O. Persky, Jonathan W. Friedberg and Steven H. Bernstein and has published in prestigious journals such as Angewandte Chemie International Edition, Journal of Clinical Oncology and Blood.

In The Last Decade

Xiaofei Zhou

75 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Xiaofei Zhou United States	20	455	431	369	162	149	79	1.2k
Yuji Mishima Japan	29	946 2.1×	1.1k 2.5×	86 0.2×	54 0.3×	292 2.0×	94	2.3k
Swati Gupta United States	20	335 0.7×	679 1.6×	272 0.7×	27 0.2×	37 0.2×	45	1.3k
Rachel A. Kudgus United States	15	351 0.8×	474 1.1×	62 0.2×	175 1.1×	79 0.5×	24	1.8k
Bing Dong China	26	416 0.9×	1.1k 2.5×	103 0.3×	30 0.2×	75 0.5×	93	2.1k
M. Margarida Bernardo United States	27	1.3k 2.8×	929 2.2×	122 0.3×	21 0.1×	46 0.3×	34	2.6k
Yuxuan Wang United States	24	476 1.0×	815 1.9×	45 0.1×	148 0.9×	282 1.9×	80	3.1k
Nicole R. Davis United States	14	427 0.9×	516 1.2×	133 0.4×	19 0.1×	92 0.6×	17	1.9k
Cheng Cheng China	22	222 0.5×	775 1.8×	50 0.1×	132 0.8×	55 0.4×	75	1.8k
Kara L. Vine Australia	23	435 1.0×	843 2.0×	58 0.2×	148 0.9×	42 0.3×	57	2.1k

Countries citing papers authored by Xiaofei Zhou

Since Specialization

Citations

This map shows the geographic impact of Xiaofei Zhou's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaofei Zhou with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaofei Zhou more than expected).

Fields of papers citing papers by Xiaofei Zhou

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaofei Zhou. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaofei Zhou. The network helps show where Xiaofei Zhou may publish in the future.

Co-authorship network of co-authors of Xiaofei Zhou

This figure shows the co-authorship network connecting the top 25 collaborators of Xiaofei Zhou. A scholar is included among the top collaborators of Xiaofei Zhou based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xiaofei Zhou. Xiaofei Zhou is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Xiaofei, et al.. (2025). Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure‐Response Analysis. Clinical Pharmacology & Therapeutics. 117(6). 1803–1810.

Zhou, Xiaofei, Boris Grinshpun, Adekemi Taylor, et al.. (2025). Population Pharmacokinetics of Fruquintinib, a Selective Oral Inhibitor of VEGFR ‐1, ‐2, and ‐3, in Patients with Refractory Metastatic Colorectal Cancer. The Journal of Clinical Pharmacology. 65(7). 873–884. 2 indexed citations

Gao, Chao, Guijuan Wei, Chunyang Wang, et al.. (2023). In situ topologically induced metastable phase Ni/r-Ni(OH)2@C heterostructures with abundant oxygen vacancies as efficient bifunctional electrocatalysts for energy-saving hydrogen production. Journal of Alloys and Compounds. 959. 170545–170545. 11 indexed citations

Kuboki, Yasutoshi, Toshio Shimizu, Kan Yonemori, et al.. (2022). Safety, Tolerability, and Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Inhibitor, in Patients with Advanced Solid Tumors: A Phase I First-in-Human Study. Cancer Research Communications. 2(11). 1426–1435. 7 indexed citations

Steeghs, Neeltje, et al.. (2022). A phase 1 open-label study to assess the relative bioavailability of TAK-931 tablets in reference to powder-in-capsule in patients with advanced solid tumors. Investigational New Drugs. 41(1). 53–59. 2 indexed citations

Zhou, Xiaofei, Ulka N. Vaishampayan, Devalingam Mahalingam, et al.. (2022). Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Investigational New Drugs. 40(5). 1042–1050. 7 indexed citations

Zhou, Xiaofei, Farhad Sedarati, Douglas V. Faller, et al.. (2020). Phase I study assessing the mass balance, pharmacokinetics, and excretion of [14C]-pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors. Investigational New Drugs. 39(2). 488–498. 19 indexed citations

Zhou, Xiaofei, Yuexian Li, Lawrence H. Cohen, et al.. (2020). Biotransformation Pathways and Metabolite Profiles of Oral [14C]Alisertib (MLN8237), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors. Drug Metabolism and Disposition. 48(3). 217–229. 13 indexed citations

Zhou, Xiaofei, Shengang Xu, Yingliang Liu, & Shaokui Cao. (2018). Mechanistic study on metal-free acetylene hydrochlorination catalyzed by imidazolium-based ionic liquids. Molecular Catalysis. 461. 73–79. 25 indexed citations

10.

Zhou, Xiaofei, John Nemunaitis, Shubham Pant, et al.. (2017). Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies. Investigational New Drugs. 36(2). 240–247. 6 indexed citations

11.

Zhou, Xiaofei, Jonathan Pace, Tao Lv, et al.. (2016). Effect of the sonic hedgehog receptor smoothened on the survival and function of dopaminergic neurons. Experimental Neurology. 283(Pt A). 235–245. 23 indexed citations

12.

Adjei, Alex A., Patricia LoRusso, Antoni Ribas, et al.. (2016). A phase I dose-escalation study of TAK-733, an investigational oral MEK inhibitor, in patients with advanced solid tumors. Investigational New Drugs. 35(1). 47–58. 29 indexed citations

13.

Falchook, Gerald S., Xiaofei Zhou, Karthik Venkatakrishnan, et al.. (2015). Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors. Drugs in R&D. 16(1). 45–52. 9 indexed citations

14.

Huck, Jessica J., Mengkun Zhang, Jerome T. Mettetal, et al.. (2014). Translational Exposure–Efficacy Modeling to Optimize the Dose and Schedule of Taxanes Combined with the Investigational Aurora A Kinase Inhibitor MLN8237 (Alisertib). Molecular Cancer Therapeutics. 13(9). 2170–2183. 27 indexed citations

15.

Falchook, Gerald S., Razelle Kurzrock, Launce Gouw, et al.. (2014). Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study. Investigational New Drugs. 32(6). 1181–1187. 31 indexed citations

16.

Liu, Yang, Jun Shi, Xiaofei Zhou, & Shaokui Cao. (2014). Hierarchically organization of biomineralized alginate beads for dual stimuli-responsive drug delivery. International Journal of Biological Macromolecules. 73. 1–8. 16 indexed citations

17.

Zhou, Xiaofei, Wei Cheng, & Richard G. Compton. (2014). Doping of Single Polymeric Nanoparticles. Angewandte Chemie International Edition. 53(46). 12587–12589. 16 indexed citations

18.

Friedberg, Jonathan W., Daruka Mahadevan, Daniel O. Persky, et al.. (2013). Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. Journal of Clinical Oncology. 32(1). 44–50. 161 indexed citations

19.

Kelly, Kevin R., Thomas C. Shea, André Goy, et al.. (2013). Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Investigational New Drugs. 32(3). 489–499. 61 indexed citations

20.

Matulonis, Ursula A., Sudarshan Sharma, Shekhar Ghamande, et al.. (2012). Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. Gynecologic Oncology. 127(1). 63–69. 111 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact